238 related articles for article (PubMed ID: 17532236)
21. Clinical relevance of MRD in children undergoing allogeneic stem cell transplantation for ALL.
Goulden N; Steward C
Best Pract Res Clin Haematol; 2002 Mar; 15(1):59-70. PubMed ID: 11987916
[TBL] [Abstract][Full Text] [Related]
22. Bone marrow minimal disseminated disease (MDD) and minimal residual disease (MRD) in childhood T-cell lymphoblastic lymphoma stage III, detected by flow cytometry (FC) and real-time quantitative polymerase chain reaction (RQ-PCR).
Stark B; Avigad S; Luria D; Manor S; Reshef-Ronen T; Avrahami G; Yaniv I
Pediatr Blood Cancer; 2009 Jan; 52(1):20-5. PubMed ID: 19006253
[TBL] [Abstract][Full Text] [Related]
23. Risk-adapted treatment of pediatric acute lymphoblastic leukemia.
Jeha S; Pui CH
Hematol Oncol Clin North Am; 2009 Oct; 23(5):973-90, v. PubMed ID: 19825448
[TBL] [Abstract][Full Text] [Related]
24. [Prognostic value of the initial response to corticosteroids for children with acute lymphoblastic leukemia].
Klimza MJ; Sońta-Jakimczyk DJ
Wiad Lek; 2005; 58(11-12):622-5. PubMed ID: 16594471
[TBL] [Abstract][Full Text] [Related]
25. Allogeneic transplantation for childhood ALL.
Mehta PA; Davies SM
Bone Marrow Transplant; 2008 Jan; 41(2):133-9. PubMed ID: 17994118
[TBL] [Abstract][Full Text] [Related]
26. Hematopoietic stem cell transplantation for adults with acute lymphoblastic leukemia.
Zuckerman T; Rowe JM
Curr Opin Hematol; 2009 Nov; 16(6):453-9. PubMed ID: 19652598
[TBL] [Abstract][Full Text] [Related]
27. Therapy for childhood acute lymphoblastic leukemia.
Cassano WF; Eskenazi AE; Frantz CN
Curr Opin Oncol; 1993 Jan; 5(1):42-52. PubMed ID: 8427893
[TBL] [Abstract][Full Text] [Related]
28. Minimal residual disease as a surrogate marker for risk assignment to ALL patients.
Cazzaniga G; Gaipa G; Rossi V; Biondi A
Rev Clin Exp Hematol; 2003 Sep; 7(3):292-323. PubMed ID: 15024971
[TBL] [Abstract][Full Text] [Related]
29. Treatment options for newly diagnosed patients with adult acute lymphoblastic leukemia.
Lamanna N; Weiss M
Curr Hematol Rep; 2004 Jan; 3(1):40-6. PubMed ID: 14695849
[TBL] [Abstract][Full Text] [Related]
30. Results of syngeneic hematopoietic stem cell transplantation for acute leukemia: risk factors for outcomes of adults transplanted in first complete remission.
Fouillard L; Labopin M; Gratwohl A; Gluckman E; Frassoni F; Beelen DW; Willemze R; Montserrat E; Blaise D; Atienza AI; Sierra J; Santos M; Gorin NC; Rocha V;
Haematologica; 2008 Jun; 93(6):834-41. PubMed ID: 18469352
[TBL] [Abstract][Full Text] [Related]
31. Early resistance to therapy during induction in childhood acute lymphoblastic leukemia.
Brisco MJ; Sykes PJ; Dolman G; Hughes E; Neoh SH; Peng L; Snell LE; Toogood IR; Rice MS; Morley AA
Cancer Res; 2000 Sep; 60(18):5092-6. PubMed ID: 11016634
[TBL] [Abstract][Full Text] [Related]
32. [Prognostic factors for childhood acute non-mature B-lymphoblastic leukemia].
Jiang H; Gu LJ; Xue HL; Tang JY; Chen J; Pan C; Chen J; Xu C; Dong L; Zhou M
Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun; 10(3):290-4. PubMed ID: 18554450
[TBL] [Abstract][Full Text] [Related]
33. [Current therapeutic strategies in acute lymphoblastic leukemia in the adult].
Thomas X; Le QH
Bull Cancer; 2003 Oct; 90(10):833-50. PubMed ID: 14706913
[TBL] [Abstract][Full Text] [Related]
34. Induction death and treatment-related mortality in first remission of children with acute lymphoblastic leukemia: a population-based analysis of the Austrian Berlin-Frankfurt-Münster study group.
Prucker C; Attarbaschi A; Peters C; Dworzak MN; Pötschger U; Urban C; Fink FM; Meister B; Schmitt K; Haas OA; Gadner H; Mann G;
Leukemia; 2009 Jul; 23(7):1264-9. PubMed ID: 19212332
[TBL] [Abstract][Full Text] [Related]
35. The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Lee S; Kim YJ; Chung NG; Lim J; Lee DG; Kim HJ; Min CK; Lee JW; Min WS; Kim CC
Cancer; 2009 Feb; 115(3):561-70. PubMed ID: 19117346
[TBL] [Abstract][Full Text] [Related]
36. Remaining problems in the staging and treatment of childhood lymphoblastic leukemia.
Bleyer WA
Am J Pediatr Hematol Oncol; 1989; 11(4):371-9. PubMed ID: 2694853
[TBL] [Abstract][Full Text] [Related]
37. Childhood acute lymphoblastic leukaemia and relapse.
Gaynon PS
Br J Haematol; 2005 Dec; 131(5):579-87. PubMed ID: 16351633
[TBL] [Abstract][Full Text] [Related]
38. Monitoring residual disease in acute lymphoblastic leukemia: therapeutic implications.
Roberts WM; Zipf TF; Kitchingman GR; Tubergen DG; Estrov Z
Cytokines Mol Ther; 1995 Mar; 1(1):65-9. PubMed ID: 9384665
[TBL] [Abstract][Full Text] [Related]
39. Prognostic factors for leukemic induction failure in children with acute lymphoblastic leukemia and outcome after salvage therapy: the FRALLE 93 study.
Oudot C; Auclerc MF; Levy V; Porcher R; Piguet C; Perel Y; Gandemer V; Debre M; Vermylen C; Pautard B; Berger C; Schmitt C; Leblanc T; Cayuela JM; Socie G; Michel G; Leverger G; Baruchel A
J Clin Oncol; 2008 Mar; 26(9):1496-503. PubMed ID: 18349402
[TBL] [Abstract][Full Text] [Related]
40. Copy number alterations in childhood acute lymphoblastic leukemia and their association with minimal residual disease.
Steinemann D; Cario G; Stanulla M; Karawajew L; Tauscher M; Weigmann A; Göhring G; Ludwig WD; Harbott J; Radlwimmer B; Bartram C; Lichter P; Schrappe M; Schlegelberger B
Genes Chromosomes Cancer; 2008 Jun; 47(6):471-80. PubMed ID: 18311775
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
